PL3898607T3 - Glutaran 3-(1,2,3,6-tetrahydropirydyn-2-ylo)pirydyny lub jego farmaceutycznie dopuszczalny solwat - Google Patents
Glutaran 3-(1,2,3,6-tetrahydropirydyn-2-ylo)pirydyny lub jego farmaceutycznie dopuszczalny solwatInfo
- Publication number
- PL3898607T3 PL3898607T3 PL19829499.3T PL19829499T PL3898607T3 PL 3898607 T3 PL3898607 T3 PL 3898607T3 PL 19829499 T PL19829499 T PL 19829499T PL 3898607 T3 PL3898607 T3 PL 3898607T3
- Authority
- PL
- Poland
- Prior art keywords
- tetrahydropyridin
- pharmaceutically acceptable
- acceptable solvate
- glutarate
- pyridine
- Prior art date
Links
- YAXCSXPWFPMOGI-UHFFFAOYSA-N pentanedioic acid 3-(1,2,3,6-tetrahydropyridin-2-yl)pyridine Chemical compound OC(=O)CCCC(O)=O.C1NC(CC=C1)c1cccnc1 YAXCSXPWFPMOGI-UHFFFAOYSA-N 0.000 title 1
- 239000012453 solvate Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18213200 | 2018-12-17 | ||
| PCT/EP2019/085598 WO2020127225A1 (en) | 2018-12-17 | 2019-12-17 | 3-(1,2,3,6-tetrahydropyridin-2-yl)pyridine glutarate or a pharmaceutically acceptable solvate thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3898607T3 true PL3898607T3 (pl) | 2024-03-18 |
Family
ID=64744512
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL19829499.3T PL3898607T3 (pl) | 2018-12-17 | 2019-12-17 | Glutaran 3-(1,2,3,6-tetrahydropirydyn-2-ylo)pirydyny lub jego farmaceutycznie dopuszczalny solwat |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US12281093B2 (pl) |
| EP (1) | EP3898607B1 (pl) |
| JP (1) | JP2022514283A (pl) |
| KR (1) | KR20210104666A (pl) |
| CN (1) | CN113039180A (pl) |
| AU (1) | AU2019407661B2 (pl) |
| BR (1) | BR112021009580A2 (pl) |
| CA (1) | CA3116524A1 (pl) |
| CL (1) | CL2021001583A1 (pl) |
| CO (1) | CO2021009186A2 (pl) |
| EC (1) | ECSP21052586A (pl) |
| ES (1) | ES2964561T3 (pl) |
| HU (1) | HUE063731T2 (pl) |
| IL (1) | IL283923B2 (pl) |
| MX (1) | MX2021006867A (pl) |
| PH (1) | PH12021550875A1 (pl) |
| PL (1) | PL3898607T3 (pl) |
| UA (1) | UA128729C2 (pl) |
| WO (1) | WO2020127225A1 (pl) |
| ZA (1) | ZA202102058B (pl) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112023003114A2 (pt) * | 2020-09-03 | 2023-04-04 | Philip Morris Products Sa | Composições em pó ativas de baixa higroscopicidade liofilizadas |
| US12594238B2 (en) * | 2020-09-03 | 2026-04-07 | Philip Morris Products S.A. | Low hygroscopicity active powder compositions |
| CN116171149A (zh) | 2020-09-03 | 2023-05-26 | 菲利普莫里斯生产公司 | 喷雾干燥的低吸湿性活性粉末组合物 |
| WO2022148850A1 (en) * | 2021-01-07 | 2022-07-14 | Philip Morris Products S.A. | Compositions comprising anatabine and uses thereof |
| CN118924725B (zh) * | 2024-09-09 | 2025-11-21 | 中国农业大学 | 3,3-二甲基戊二酸在制备治疗自闭症谱系障碍产品中的用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5582837A (en) | 1992-03-25 | 1996-12-10 | Depomed, Inc. | Alkyl-substituted cellulose-based sustained-release oral drug dosage forms |
| US5972389A (en) | 1996-09-19 | 1999-10-26 | Depomed, Inc. | Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter |
| US6210710B1 (en) | 1997-04-28 | 2001-04-03 | Hercules Incorporated | Sustained release polymer blend for pharmaceutical applications |
| US5942244A (en) | 1997-07-31 | 1999-08-24 | Farmo-Nat Ltd. | Local oral herbal slow release tablets |
| US6090411A (en) | 1998-03-09 | 2000-07-18 | Temple University | Monolithic tablet for controlled drug release |
| US7458374B2 (en) | 2002-05-13 | 2008-12-02 | Alexza Pharmaceuticals, Inc. | Method and apparatus for vaporizing a compound |
| US7766013B2 (en) | 2001-06-05 | 2010-08-03 | Alexza Pharmaceuticals, Inc. | Aerosol generating method and device |
| US6723340B2 (en) | 2001-10-25 | 2004-04-20 | Depomed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
| CN2719043Y (zh) | 2004-04-14 | 2005-08-24 | 韩力 | 雾化电子烟 |
| US8207346B2 (en) | 2010-03-23 | 2012-06-26 | Rock Creek Pharmaceuticals, Inc. | Methods of synthesizing anatabine |
| EP3871674B1 (en) | 2010-03-23 | 2024-12-25 | Philip Morris Products S.A. | Use of anatabine for reducing blood serum levels of c-reactive protein in an individual |
| US8241680B2 (en) | 2010-06-30 | 2012-08-14 | Rock Creek Pharmaceuticals, Inc. | Nutraceutical product containing anatabine and yerba maté |
| US20120245202A1 (en) * | 2010-09-17 | 2012-09-27 | Rock Creek Pharmaceuticals, Inc. | Methods and products for treating inflammation |
| US20120325228A1 (en) | 2011-06-23 | 2012-12-27 | Williams Jonnie R | Alkaloid composition for e-cigarette |
| CN108578405A (zh) * | 2011-08-29 | 2018-09-28 | 菲利普莫里斯产品有限公司 | 用于抗炎支持的产品 |
| WO2015009500A1 (en) | 2013-07-19 | 2015-01-22 | Williams Jonnie R | Volatilized delivery of anatabine for treatment of substance addiction |
-
2019
- 2019-12-17 PL PL19829499.3T patent/PL3898607T3/pl unknown
- 2019-12-17 CA CA3116524A patent/CA3116524A1/en active Pending
- 2019-12-17 WO PCT/EP2019/085598 patent/WO2020127225A1/en not_active Ceased
- 2019-12-17 ES ES19829499T patent/ES2964561T3/es active Active
- 2019-12-17 EP EP19829499.3A patent/EP3898607B1/en active Active
- 2019-12-17 BR BR112021009580-2A patent/BR112021009580A2/pt unknown
- 2019-12-17 JP JP2021534811A patent/JP2022514283A/ja active Pending
- 2019-12-17 HU HUE19829499A patent/HUE063731T2/hu unknown
- 2019-12-17 UA UAA202101679A patent/UA128729C2/uk unknown
- 2019-12-17 KR KR1020217015007A patent/KR20210104666A/ko not_active Ceased
- 2019-12-17 US US17/289,794 patent/US12281093B2/en active Active
- 2019-12-17 IL IL283923A patent/IL283923B2/en unknown
- 2019-12-17 MX MX2021006867A patent/MX2021006867A/es unknown
- 2019-12-17 CN CN201980076050.9A patent/CN113039180A/zh active Pending
- 2019-12-17 AU AU2019407661A patent/AU2019407661B2/en active Active
-
2021
- 2021-03-26 ZA ZA2021/02058A patent/ZA202102058B/en unknown
- 2021-04-15 PH PH12021550875A patent/PH12021550875A1/en unknown
- 2021-06-16 CL CL2021001583A patent/CL2021001583A1/es unknown
- 2021-07-14 CO CONC2021/0009186A patent/CO2021009186A2/es unknown
- 2021-07-16 EC ECSENADI202152586A patent/ECSP21052586A/es unknown
-
2025
- 2025-03-19 US US19/084,012 patent/US20250243178A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| UA128729C2 (uk) | 2024-10-09 |
| KR20210104666A (ko) | 2021-08-25 |
| IL283923B2 (en) | 2025-08-01 |
| MX2021006867A (es) | 2021-07-02 |
| PH12021550875A1 (en) | 2021-10-18 |
| ECSP21052586A (es) | 2021-08-31 |
| WO2020127225A1 (en) | 2020-06-25 |
| ZA202102058B (en) | 2022-09-28 |
| CL2021001583A1 (es) | 2021-11-26 |
| BR112021009580A2 (pt) | 2021-08-17 |
| CO2021009186A2 (es) | 2021-08-30 |
| AU2019407661A1 (en) | 2021-04-29 |
| CN113039180A (zh) | 2021-06-25 |
| US12281093B2 (en) | 2025-04-22 |
| EP3898607B1 (en) | 2023-10-18 |
| IL283923B1 (en) | 2025-04-01 |
| US20210395218A1 (en) | 2021-12-23 |
| CA3116524A1 (en) | 2020-06-25 |
| IL283923A (en) | 2021-07-29 |
| EP3898607C0 (en) | 2023-10-18 |
| EP3898607A1 (en) | 2021-10-27 |
| AU2019407661B2 (en) | 2024-07-25 |
| ES2964561T3 (es) | 2024-04-08 |
| US20250243178A1 (en) | 2025-07-31 |
| JP2022514283A (ja) | 2022-02-10 |
| HUE063731T2 (hu) | 2024-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL283923A (en) | 3-(6,3,2,1-tetrahydropyridin-2-yl)pyridine glutarate or its pharmaceutically acceptable solvate | |
| DK3846904T3 (da) | 5-morpholin-4-yl-pyrazolo[4,3-b]pyridinderivater | |
| ZA202204675B (en) | New methylquinazolinone derivatives | |
| ZA201905098B (en) | A novel isoindoline derivative, a pharmaceutical composition and use thereof | |
| SG11202011685QA (en) | 2,3-dihydro-1h-pyrrolizine-7-formamide derivative and application thereof | |
| IL276952A (en) | History of 4,2-diaminoquinazolines and their medicinal uses | |
| IL277860A (en) | A method for the preparation of 5,4,2-triconverted 4,2,1-triazolone | |
| IL288950A (en) | History of pyridine-3-yl | |
| PH12020550649A1 (en) | Anti-hbv tetrahydroisoxazolo[4,3-c]pyridine compounds | |
| GB202015822D0 (en) | 66.123.142648/01 | |
| SG11202104371XA (en) | 1,3,4-oxadiazolone compound and pharmaceutical | |
| GB2586063B (en) | Modular earphone | |
| SG11202012760SA (en) | METHOD FOR PRODUCING a-AZIDOANILINE DERIVATIVE OR a,a'-DIAZIDE DERIVATIVE | |
| PL4021900T3 (pl) | 2,2,6-trimetylo-4,5-dihydro-3h-oksepina jako składnik aromatowy | |
| GB2596742B (en) | Double metal patterning | |
| GB2576392B (en) | Widener | |
| WO2019203748A3 (en) | The composition comprising raloxifene with at least one antipsychotic agent | |
| EP3925957A4 (en) | 1,3-DIOXOLANE DERIVATIVE | |
| GB202013791D0 (en) | Tidysqueeze 9 | |
| FIC20190036I1 (fi) | Naldemediini tai sen farmaseuttisesti hyväksyttävä suola tai solvaatti, erityisesti tosylaattisuola | |
| GB201918773D0 (en) | TidySqueeze 8 | |
| PH32018001114S1 (en) | Cabinet (sn 398) | |
| ZAF201900429S (en) | Shin later | |
| GB201913527D0 (en) | Nodens 2 | |
| GB201910340D0 (en) | CAERvest 1 |